WELCOME to Covid-19 Commons.

Covid-19 Commons is a global resource aiming to:

  • Summarize all current efforts relating to the treatment of Covid-19. We share here Biovista Vizit graphs that represent the main biological entities that are central to each research hypothesis we identify from public resources. We will keep updating this list with new hypotheses, as we are made aware of them.
  • Support collaboration in the search for an understanding of the biology of SARS-CoV-2 and the development of novel treatments for Covid-19. The Biovista Vizit graphs listed are actionable. Clicking on these graphs will take you straight into the Biovista Vizit environment. Feel free to use each graph as a starting point to assess and expand on the reported findings, or to create your own hypotheses. If you wish to share your hypothesis, send us an email with your Biovista Vizit graph and we will add it to the Covid-19 Commons.

Covid-10 Commons organizes current research work in 2 sections:

  • Section A: lists graphs that explore hypotheses on the biology of SARS-CoV-2.
  • Section B: lists graphs that explore hypotheses on possible treatments for Covid-19.

In both sections one graph is created for each hypothesis, and is annotated with purported mechanism of action (MoA) information as this is reported in the .

Note: Biovista Vizit graphs display associations between terms in the Vizit database. The term “covid-19” is currently being added and will be made available in the next Vizit database release.

Section A: SARS-CoV-2 Biology

Lists graphs that explore hypotheses on the biology of SARS-CoV-2.

Graph A1: ACE2, TMPRSS2, Acute Lung Injury, ARDS, and Lung Fibrosis.

Title: ACE2, TMPRSS2, Acute Lung Injury, ARDS, and Lung Fibrosis.
Reference: Biovista white paper
Contact: info@biovista.com
Context: The graph visualizes the relationships between genes ACE2 and TMPRSS2 and specific manifestations of COVID-19, such as Acute Lung Injury, ARDS and Lung Fibrosis through a network of specific biological entities such as Cell Types, Pathways and Anatomical Locations that are likely implicated in the pathogenesis of the disease.

Section B: Covid-19 novel treatment hypotheses

Lists graphs that explore hypotheses on possible treatments for Covid-19.

Graph B1: Remdesivir

Title: Cardiovascular considerations for repositioning remdesivir, hydroxychloroquine, chloroquine, and interleukin (IL)-6 inhibitors in COVID-19 patients.
Context: Patients with COVID-19 often also have cardiovascular challenges and associated comorbidities. Understanding how repositioned drugs to treat COVID-19 may impact the cardiovascular health of patients is important. Targets of the drugs are included (e.g. RNA dependent RNA polymerase, target of remdesivir, IL-7, target of IL-6 inhibitors).

Graph B2: Azithromycin

Title: Mechanistic analysis of Azithromycin
Context: Azithromycin is being tested in COVID-19 patients. Although it is a potent antibiotic, in the COVID-19 setting, it likely acts as an anti-inflammatory agent. Its exact MoA in the disease, however, remains to be elucidated.

Graph B3: Actemra

Title: Mechanistic analysis of Actemra
Context: Acterma is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients.

Graph B4: Ivermectin

Title: Mechanistic analysis of Ivermectin
Context: Ivermectin is an anti-parasitic agent that has shown promise against the virus in vitro. Its potential mechanism of action (MoA) in COVID-19, is poorly understood.

Graph B5: Calquence

Title: Mechanistic analysis of Calquence
Context: Calquence is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19.

Graph B6: Combination IFB-a2b chlorpheniramine, ibuprofen

Title: Mechanistic analysis of combination IFB-a2b chlorpheniramine, ibuprofen
Context: Chlorphenamine is a known antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis, whereas Ibuprofen is a potent nonsteroidal anti-inflammatory drug (NSAID). Combination of chlorpheniramine and ibuprofen combination have long been postulated to treat common cold and its symptoms. Role and efficacy in the COVID-19 remains to be elucidated.

Graph B7: Soliris

Title: Mechanistic analysis of Soliris
Context: Soliris is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The MoA of this drug remains to be elucidated in COVID-19.

Graph B8: Amantadine

Title: Mechanistic analysis of Amantadine
Context: Amantadine is an anti-viral drug which is also used in Parkinson’s disease. The drug has been shown to reduce viral load in the context of the influenza virus, and in the COVID-19 setting, it may be able to decrease the viral load in SARS-CoV-2 positive patients.

Graph B9: Angiotensins

Title: Mechanistic analysis of the angiotensin class.
Context: There is growing amount of evidence to suggest the use of angiotensins for the treatment of COVID-19.

Graph B10: Atorvastatin

Title: Mechanistic analysis of a statin.
Context: Repositioning of statins. Statins such as atorvastatin are potent cholesterol-lowering dugs that are currently tested against COVID-19.